droplet-based PCR
The firm expects growth in its ddPCR business this year as it launches new products and the biopharma segment begins to recover from a funding slump.
Bio-Rad Q2 Revenues Fall 2 Percent
The sales decline was largely due to a slowdown in productivity related to the recent launch of the company's global enterprise resource planning system in Western Europe.